您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Mdivi-1(Mitochondrial division inhibitor 1)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Mdivi-1(Mitochondrial division inhibitor 1)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Mdivi-1(Mitochondrial division inhibitor 1)图片
CAS NO:338967-87-6
规格:≥98%
包装与价格:
包装价格(元)
10mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
Mdivi-1 (Mitochondrial Division Inhibitor 1; Mdivi 1; Mdivi1) is a potent selective and cell-permeable inhibitor of mitochondrial division DRP1 (dynamin-related GTPase) and mitochondrial division Dynamin I (Dnm1) with the potential for treating stroke, myocardial infarction, and neurodegenerative disease. It inhibits DRP1 and Dnm1 with IC50s of 1-10 μM. Mdivi-1 inhibits apoptosis by inhibiting mitochondrial outer membrane permeabilization. Mdivi-1 treatment blocked apoptotic cell death in ischemic retina, and significantly increased RGC survival at 2 weeks after ischemia. Mdivi-1 is the first selective inhibitor of mitochondrial division dynamins and represents a class of therapeutics for stroke, myocardial infarction, and neurodegenerative diseases.
理化性质和储存条件
Molecular Weight (MW)353.22
FormulaC15H10Cl2N2O2S
CAS No.338967-87-6
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 70 mg/mL (198.2 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In vivo)5% DMSO+40% PEG 300+ddH2O: 7mg/mL
Synonyms

Mdivi-1; Mitochondrial Division Inhibitor 1; Mdivi 1; Mdivi1.

Chemical Name: 3-(2,4-dichloro-5-methoxyphenyl)-2-thioxo-2,3-dihydroquinazolin-4(1H)-one

SMILES Code: O=C1N(C2=CC(OC)=C(Cl)C=C2Cl)C(NC3=C1C=CC=C3)=S

Exact Mass: 351.984

实验参考方法
In Vitro

In vitro activity: Mdivi-1 is a cell-permeable quinazolinone compound that inhibits yeast (Dnm1) and mammalian (Drp1) division DRPs (dynamin-related GTPases) and effectively induces mitochondrial fusion into net-like structures in a reversible manner. Cell-free studies indicate that mdivi-1 blocks Dnm1 ATPase activity (IC50<10 μM) and self-assembly by an allosteric modulation-based mechanism. Mdivi-1 is shown to effectively suppress STS- as well as C8-Bid-induced MOMP (Mitochondrial Outer Membrane Permeabilization) in HeLa cultures and in cell-free murine liver mitochondria preparations, respectively, as assessed by cytochrome C release. In cells, mdivi-1 retards apoptosis by inhibiting mitochondrial outer membrane permeabilization. In principle, mivi-1 represents a class of therapeutics for stroke, myocardial infarction, and neurodegenerative diseases.


Kinase Assay: All GTPase assay reactions are started in a 200 μL volume, of which 150 μL is placed into the well of a 96-well plate. Depletion of NADH, as monitored by reading the A340 of the reaction, is measured every 20 s for a total of 40 min using a SpectraMAX 250 96-well plate reader. Spectrophotometric data are transferred to Excel and the measured steady state depletion of NADH over time is converted to protein activity.


Cell Assay: The most efficacious inhibitor, mdivi-1 attenuates mitochondrial division in yeast and mammalian cells by selectively inhibiting the mitochondrial Drp1-mediated division dynamin. Mdivi-1 potently blocks Bid-activated Bax/Bak-dependent cytochrome c release from mitochondria.

In VivoDrp1 and GFAP protein expression is significantly increased in the early neurodegenerative events of ischemic mouse retina. Mdivi-1 treatment blocks apoptotic cell death in ischemic retina, and significantly increases RGC survival at 2 weeks after ischemia. In the normal mouse retina, Drp1 is expressed in the ganglion cell layer (GCL) as well as the inner plexiform layer, the inner nuclear layer (INL), and the outer plexiform layer (OPL). In the GCL, Drp1 immunoreactivity is strong in RGCs. While Drp1 protein expression is increased in the GCL of vehicle-treated ischemic retina at 12 hours. Mdivi-1 treatment does not change this increase of Drp1 protein expression but significantly decreased GFAP protein expression.
Animal modelC57BL/6 mice
Formulation & DosageDissolved in DMSO; 50 mg/kg; i.p. injection
ReferencesDev Cell. 2008 Feb;14(2):193-204; Invest Ophthalmol Vis Sci. 2011 Apr 27;52(5):2837-43.